-
Je něco špatně v tomto záznamu ?
Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center
B. Voglová, M. Zahradnická, P. Girman, J. Kríž, Z. Berková, T. Koblas, E. Vávrová, L. Németová, L. Kosinová, D. Habart, E. Fábryová, E. Dovolilová, I. Leontovyc, T. Neškudla, J. Peregrin, J. Kovác, K. Lipár, M. Kocík, T. Marada, J. Svoboda, F. Saudek,
Jazyk angličtina Země Belgie
Typ dokumentu časopisecké články
Grantová podpora
NV15-26746A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 2004 do Před 1 rokem
PubMed Central
od 2004 do 2023
Europe PubMed Central
od 2004 do 2017
PubMed
28632818
DOI
10.1900/rds.2017.14.10
Knihovny.cz E-zdroje
- MeSH
- C-peptid krev MeSH
- diabetes mellitus 1. typu epidemiologie etiologie terapie MeSH
- dospělí MeSH
- hodnocení rizik MeSH
- hypoglykemie epidemiologie terapie MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- následné studie MeSH
- přežívání štěpu MeSH
- retrospektivní studie MeSH
- syndrom MeSH
- transplantace Langerhansových ostrůvků * škodlivé účinky metody MeSH
- transplantace slinivky břišní * škodlivé účinky metody MeSH
- výběrové chování MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. AIM: This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. METHODS: We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. RESULTS: Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. CONCLUSION: This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013150
- 003
- CZ-PrNML
- 005
- 20220329150847.0
- 007
- ta
- 008
- 190405s2017 be f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1900/RDS.2017.14.10 $2 doi
- 035 __
- $a (PubMed)28632818
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a be
- 100 1_
- $a Hagerf, Barbora $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0271328
- 245 10
- $a Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center / $c B. Voglová, M. Zahradnická, P. Girman, J. Kríž, Z. Berková, T. Koblas, E. Vávrová, L. Németová, L. Kosinová, D. Habart, E. Fábryová, E. Dovolilová, I. Leontovyc, T. Neškudla, J. Peregrin, J. Kovác, K. Lipár, M. Kocík, T. Marada, J. Svoboda, F. Saudek,
- 520 9_
- $a BACKGROUND: Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. AIM: This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. METHODS: We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. RESULTS: Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. CONCLUSION: This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a C-peptid $x krev $7 D002096
- 650 _2
- $a výběrové chování $7 D002755
- 650 _2
- $a diabetes mellitus 1. typu $x epidemiologie $x etiologie $x terapie $7 D003922
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a přežívání štěpu $7 D006085
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemie $x epidemiologie $x terapie $7 D007003
- 650 12
- $a transplantace Langerhansových ostrůvků $x škodlivé účinky $x metody $7 D016381
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a transplantace slinivky břišní $x škodlivé účinky $x metody $7 D016035
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a syndrom $7 D013577
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zahradnická, Martina $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Girman, Peter $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Kríž, Jan $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Berková, Zuzana $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Koblas, Tomáš $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Vávrová, Ema $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Németová, Lenka $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Kosinová, Lucie $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Habart, David $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Fábryová, Eva $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Dovolilová, Eva $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Leontovyc, Ivan $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Neškudla, Tomáš $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Peregrin, Jan $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Kovác, Jozef $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Lipár, Kvetoslav $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Kocík, Matej $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Marada, Tomáš $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Svoboda, Jirí $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Saudek, František $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 773 0_
- $w MED00008952 $t The review of diabetic studies RDS $x 1613-6071 $g Roč. 14, č. 1 (2017), s. 10-21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28632818 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20220329150844 $b ABA008
- 999 __
- $a ok $b bmc $g 1392460 $s 1051455
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 14 $c 1 $d 10-21 $e 20170612 $i 1613-6071 $m The review of diabetic studies $n Rev Diabet Stud $x MED00008952
- GRA __
- $a NV15-26746A $p MZ0
- LZP __
- $a Pubmed-20190405